199 related articles for article (PubMed ID: 26689580)
1. Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ni H; Ju S
Pathol Oncol Res; 2016 Jul; 22(3):531-9. PubMed ID: 26689580
[TBL] [Abstract][Full Text] [Related]
2. [Effect of miR-202 on the growth of multiple myeloma cells via regulating B cell-activating factor and the underlying mechanism].
Yu JJ; Shen XJ; Wang XD; Ju SQ
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):886-91. PubMed ID: 24506956
[TBL] [Abstract][Full Text] [Related]
3. [miR-202 contributes to sensitizing MM cells to drug significantly via activing JNK/SAPK signaling pathway].
Zhang Y; Shen XJ; Wu XH; Cong H; Ni HB; Ju SQ; Su JY
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):987-992. PubMed ID: 27995886
[TBL] [Abstract][Full Text] [Related]
4. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
5. miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor.
Shen X; Guo Y; Yu J; Qi J; Shi W; Wu X; Ni H; Ju S
Clin Exp Med; 2016 Aug; 16(3):307-16. PubMed ID: 25971527
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.
Zhang X; Chen Y; Zhao P; Zang L; Zhang Z; Wang X
Leuk Lymphoma; 2017 Apr; 58(4):932-940. PubMed ID: 27830963
[TBL] [Abstract][Full Text] [Related]
7. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
[TBL] [Abstract][Full Text] [Related]
9. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
10. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation.
Wang X; Li C; Ju S; Wang Y; Wang H; Zhong R
Leuk Lymphoma; 2011 Oct; 52(10):1991-8. PubMed ID: 21718132
[TBL] [Abstract][Full Text] [Related]
11. TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.
Lin Z; Song D; Wei H; Yang X; Liu T; Yan W; Xiao J
J Cancer Res Clin Oncol; 2016 Jan; 142(1):239-46. PubMed ID: 26276504
[TBL] [Abstract][Full Text] [Related]
12. BAFF is involved in macrophage-induced bortezomib resistance in myeloma.
Chen J; He D; Chen Q; Guo X; Yang L; Lin X; Li Y; Wu W; Yang Y; He J; Zhang E; Yi Q; Cai Z
Cell Death Dis; 2017 Nov; 8(11):e3161. PubMed ID: 29095438
[TBL] [Abstract][Full Text] [Related]
13. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
Gullà A; Di Martino MT; Gallo Cantafio ME; Morelli E; Amodio N; Botta C; Pitari MR; Lio SG; Britti D; Stamato MA; Hideshima T; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Clin Cancer Res; 2016 Mar; 22(5):1222-33. PubMed ID: 26527748
[TBL] [Abstract][Full Text] [Related]
14. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
15. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.
Feng W; Fu Y; Zhang Y; Lv B; Li X; Zhang F; Gui R; Liu J
Int J Clin Exp Pathol; 2015; 8(9):10635-43. PubMed ID: 26617773
[TBL] [Abstract][Full Text] [Related]
16. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma].
Wang SM; Zhang TL; Jiang YM; Wu HY; Hao LM; Xing XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):395-8. PubMed ID: 21518495
[TBL] [Abstract][Full Text] [Related]
18. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
19. MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.
Han J; Chen Q
Int J Clin Exp Pathol; 2015; 8(10):12698-707. PubMed ID: 26722459
[TBL] [Abstract][Full Text] [Related]
20. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
